Oculis (NASDAQ:OCS) Sees Strong Trading Volume – What’s Next?

Shares of Oculis Holding AG (NASDAQ:OCS) saw an uptick in trading volume on Wednesday . 70,058 shares were traded during mid-day trading, a decline of 38% from the previous session’s volume of 112,347 shares.The stock last traded at $18.55 and had previously closed at $18.22.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Chardan Capital reiterated a “buy” rating and set a $28.00 price target on shares of Oculis in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Oculis in a research note on Monday. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $28.80.

Oculis Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The firm has a market capitalization of $856.66 million, a P/E ratio of -10.96 and a beta of -0.33. The stock’s 50 day simple moving average is $16.41 and its 200 day simple moving average is $13.91.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.